Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Ocean Biomedical (NASDAQ: OCEA) Receives U.S. Patent Approval Notice for New Malaria Treatment

Ocean Biomedical, Inc. (NASDAQ: OCEA) is engaged as a biopharmaceutical company, which is focused on the development and commercialization of innovative treatments for life-threatening diseases. Shares of the biopharma company are soaring 46% through early trading on Thursday, April 13, 2023. Over the past three months, Ocean Biomedical has seen average daily volume of 2.14 million shares. However, volume of 13.1 million shares or dollar volume of around $87.64 million, has already exchanged hands through early trading.

Shares of Ocean Biomedical are climbing after the company announced that its co-founder and member of the board of directors, Dr. Jonathan Kurtis, MD, has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application on a new therapeutic and prophylactic monoclonal antibody that is capable of killing falciparum malaria parasites. Ocean Biomedical says they anticipate the patent to be officially issued in the coming months.

The news comes as Dr. Kurtis and Ocean Biomedical build upon a monumental discovery that PfGARP is a potential effective vaccine target to treat malaria. Dr. Kurtis was then able to discover and produce a monoclonal antibody that is capable of binding to PfGARP and ultimately triggers the malaria parasite to kill itself.

Dr. Kurtis and his team will now work on further developing the monoclonal antibody as a potential therapeutic drug for severe malaria infection, as well as for individuals living in regions that are known for short malaria transmission seasons.

“Inducing parasite cell death via targeting PfGARP is a novel approach that has potential to launch a whole new class of anti-malarials, including mRNA-based vaccines, small molecules and the current monoclonal antibody,” said Dr. Kurtis. “Our monoclonal comes at a critical time because malaria parasites are developing resistance to current frontline therapeutics, and because the currently approved vaccine offers only very limited protection.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Ocean Biomedical (NASDAQ: OCEA) Receives U.S. Patent Approval Notice for New Malaria Treatment appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.